## TMO: Thermo Fisher Scientific Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 1.4% below STRENGTH zone (4.0-10.0%); PEG 2.14 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (38% of avg).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($564.37)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Marathon Asset Management Ltd Sells 29,919 Shares of Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20251229T120837 | Somewhat-Bullish | Relevance: 100%
- Marathon Asset Management Ltd reduced its stake in Thermo Fisher Scientific Inc. by 24.4% in the third quarter, selling 29,919 shares and now owning 92,802 shares valued at $45.05 million. Despite insider selling, Thermo Fisher outperformed Q3 earnings expectations and announced a $5 billion stock buyback program, with analysts maintaining a "Moderate Buy" consensus rating for the company.

**2. Live Oak Private Wealth LLC Has $6.62 Million Stock Position in Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20251229T120837 | Bullish | Relevance: 100%
- Live Oak Private Wealth LLC significantly increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 23.6% in the third quarter, holding shares valued at $6.62 million. Wall Street analysts maintain a "Moderate Buy" consensus rating for TMO with a target price of $616.60, following the company's strong Q3 performance, upward revised FY2025 EPS guidance, a $5.0 billion stock buyback authorization, and a declared quarterly dividend. Despite insider selling, institutional ownership remains high, indicating continued confidence in the medical research company's prospects.

**3. What Makes Thermo Fisher (TMO) a Good Investment Choice?**
- Source: Insider Monkey | 20251229T101200 | Bullish | Relevance: 100%
- Artisan Partners' "Artisan Value Fund" highlighted Thermo Fisher Scientific Inc. (NYSE: TMO) as a top contributor to returns in Q3 2025, following a strategic purchase during a market downturn. The company, a leader in life sciences tools and clinical research, is praised for its strong industry position, feasible 10% earnings growth target, solid balance sheet, and high free cash flow conversion. Artisan Partners views TMO as an attractive long-term buying opportunity despite softer market conditions and potential impacts from tariffs.

**4. Annex Advisory Services LLC Has $8.55 Million Stake in Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20251229T081651 | Somewhat-Bullish | Relevance: 100%
- Annex Advisory Services LLC significantly increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 93.7% in Q3, now holding 17,620 shares valued at approximately $8.55 million. This comes as company insiders were net sellers, offloading 149,271 shares worth about $86.5 million over the past 90 days. Despite insider sales, Thermo Fisher Scientific reported strong quarterly earnings, beating estimates, and authorized a $5.0 billion share buyback program.

**5. NovaPoint Capital LLC Takes $1.10 Million Position in Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20251228T120457 | Bullish | Relevance: 100%
- NovaPoint Capital LLC recently acquired a new stake of 2,269 shares in Thermo Fisher Scientific Inc., valued at approximately $1.10 million. This comes as other institutional investors have also adjusted their positions in the medical research company. Thermo Fisher Scientific has reported strong earnings, initiated a stock repurchase plan, and declared a quarterly dividend.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Wells Fargo | $675 | $635 | +6% |
| 2025-12-11 | Citigroup | $660 | $580 | +14% |
| 2025-12-09 | Goldman Sachs | $685 | $0 | 0% |
| 2025-12-08 | Keybanc | $750 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Wells Fargo | main | Overweight |
| 2025-12-11 | Citigroup | up | Buy |
| 2025-12-09 | Goldman Sachs | init | Buy |
| 2025-12-08 | Keybanc | up | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 4 ($8.01M) |
| Sells | 12 ($5.34M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.0% (+0.2%)
- Blackrock Inc.: 7.9% (+8.4%)
- State Street Corpora: 4.4% (-0.6%)
- JPMORGAN CHASE & CO: 3.9% (+58.9%)
- Morgan Stanley: 3.4% (-1.2%)

### Key Risks

1. Insider selling cluster: $5.3M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 4 raises (avg +11%) could attract flows.
- Momentum building: MRS_20 improving +2.1% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 2.14 elevated, pricing in significant growth expectations. Forward P/E 23.7x stretched relative to 8% growth. Balance sheet: $1.8B free cash flow. Analyst sentiment positive (4 raises, avg +11%). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $219.8B |
| Beta | 0.90 |
| 52W Range | $385.46 - $610.97 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.14 |
| Forward P/E | 23.7 |
| Current P/E | 25.7 |
| YoY Growth | 8.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -0.7% to 1.4% (+2.1% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.5pp (needs >4.0% for momentum thesis). MRS_5 at 1.1% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.67), confirming momentum. RSI neutral at 59. Volume at 38% of 20MA suggests lack of conviction. OFD pattern: +FTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.45% (CS: 70) | Neutral |
| RSI_14 | 59.0 | Neutral |
| MACD Histogram | 0.67 | Bullish |
| vs SMA20 | 1.018x | Above |
| vs SMA50 | 1.021x | Above |
| vs SMA200 | 1.207x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $584.93
- **Stop Loss:** $564.37 (3.5% risk)
- **Target:** $605.49 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 67
- **Position Value:** $39,190.31
- **Portfolio %:** 39.19%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.15x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite and defensive rotation. VIX at 14.2 (2nd percentile) signals low volatility, while positive yield curve (+58bps) and stable economic indicators support continued expansion. Market breadth at 58.7% shows decent participation, but rotation into defensive names and Fed liquidity concerns warrant measured positioning.*

### Earnings

**Next:** 2026-01-29 (Est: $6.45)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.50 | $5.79 | +5.3% |
| 2025Q2 | $5.23 | $5.36 | +2.5% |
| 2025Q1 | $5.10 | $5.15 | +0.9% |
| 2024Q4 | $5.94 | $6.10 | +2.7% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*